See today's BioWorld Asia
To read the full story, subscribe or sign in.

China’s Harbour Biomed out-licenses preclinical bispecific antibody to Astrazeneca for $350M

April 12, 2022
By Tamra Sami
Harbour Biomed Therapeutics Ltd. has out-licensed a preclinical bispecific antibody, HBM-7022, to Astrazeneca plc in a global licensing deal worth up to $350 million.
BioWorld Asia Deals and M&A China